Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

…, JG Herrera, JI Henter, F Janku… - Blood, The Journal …, 2016 - ashpublications.org
The histiocytoses are rare disorders characterized by the accumulation of macrophage,
dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults. …

Targeting the PI3K pathway in cancer: are we making headway?

F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated pathways in cancer
and, consequently, more than 40 compounds that target key components of this signalling …

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

J Polivka Jr, F Janku - Pharmacology & therapeutics, 2014 - Elsevier
Aberrations in various cellular signaling pathways are instrumental in regulating cellular
metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal …

Autophagy as a target for anticancer therapy

F Janku, DJ McConkey, DS Hong… - Nature reviews Clinical …, 2011 - nature.com
Autophagy is an important homeostatic cellular recycling mechanism responsible for
degrading unnecessary or dysfunctional cellular organelles and proteins in all living cells. …

[HTML][HTML] Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer

…, PJ O'Dwyer, D Maru, V Morris, F Janku… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
… Three patients had pretreatment and follow-up [ 18 F]fluorodeoxyglucose positron
emission tomography; two of these patients had a metabolic response with greater than 25% …

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

…, L Petruzelka, M Zemanova, L Havel, F Janku… - Lung cancer, 2004 - Elsevier
Purpose: The superiority of chemoradiotherapy (CRT) over radiation alone in locally
advanced non-small cell lung cancer (NSCLC) has been proven, but the relative merits of a …

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

…, GS Falchook, S Fu, S Piha-Paul, A Naing, F Janku… - Clinical cancer …, 2012 - AACR
F. Janku has a commercial research grant from Novartis. D. Berry is a paid consultant and
co-owner of Berry Consultants, whose clients include some of the sponsors of clinical trials …

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

…, DM Hyman, G Cavalli, F Janku… - Blood, The Journal …, 2014 - ashpublications.org
… (F) Sagittal postgadolinium T1 MRI shows thickening and enhancement of the pituitary stalk.
… (F) Sagittal postgadolinium T1 MRI shows thickening and enhancement of the pituitary stalk. …

Diverse and targetable kinase alterations drive histiocytic neoplasms

…, J Donadieu, DB Solit, DM Hyman, J Baselga, F Janku… - Cancer discovery, 2016 - AACR
F. Janku reports receiving commercial research grants from Biocartis, Foundation Medicine,
and Trovagene and is a consultant/advisory board member for Trovagene. A. Dogan is a …

[HTML][HTML] PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

F Janku, JJ Wheler, SN Westin, SL Moulder… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
… Provision of study materials or patients: Filip Janku, Jennifer J. Wheler, Shannon N.
Westin, Stacy L. … Collection and assembly of data: Filip Janku, Ignacio Garrido-Laguna …